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'Knockout' mice have been developed that lack the Huntington's
disease gene, in an effort to gain insight into the disorder and into
the pathophysiological effects of tri-nucleotide repeat expansion.
The characteristics of the mutations that cause a particular
genetic disease can often be predicted simply on the basis
of inheritance patterns. Recessively inherited disorders are
usually caused by a loss of function of the corresponding
gene product, and any mutation which destroys the func-
tion of the gene, its RNA or protein product can effect
this inheritance pattern. Dominantly inherited disorders,
on the other hand, express disease when only one of the
two copies of the gene is abnormal. Hence the biochemi-
cal defect is usually not a complete loss of function,
because one functioning normal copy of the gene is pre-
sent in each cell. Instead, most dominantly inherited dis-
orders are the result of single amino-acid changes
(missense mutations) which alter the protein product in a
novel manner to produce a protein with an aberrant (and
deleterious) function.
Dominantly inherited diseases thus fall into one of
three categories: 'change of function', in which the
abnormal protein acquires a novel activity that is del-
eterious to the cell; 'dominant negative', in which the
abnormal protein forms hetero-oligomeric complexes
with the protein produced from the normal allele of
the gene, thereby knocking out the function of the entire
protein complex; or 'haplo-insufficiency', in which a
single copy of the gene has lost function, and the 50 % of
the normal amount of protein that is produced from the
non-mutated allele is not adequate to preclude clinical
symptoms. Excellent examples of change-of-function dis-
orders are provided by sodium channel disorders, in which
missense mutations create new channel-gating properties
and result in periodic paralysis [1]. Dominant-negative
protein abnormalities are exemplified by the missense
mutations in collagen genes that lead to destruction of
collagen fibrils and result in osteogenesis imperfecta type
II [2]. An example of haplo-insufficiency is the loss of
function in one copy of the low density lipoprotein recep-
tor gene, with insufficient compensation by the good
allele, resulting in familial hypercholesterolemia [3].
Tri-nucleotide repeat expansion mutations, like those that
cause Huntington's disease, have only recently been iden-
tified, and there is considerable interest in determining how
abnormally large repeat sequences cause molecular and
clinical pathology. Diseases caused by the expansion of a
tri-nucleotide motif- in which, for example, the normal
sequence (CAG)1 0 expands to the disease-causing (CAG) 200
- now number over ten, with some of the most common
and poorly understood neurological disorders included in
this group: Huntington's disease, Fragile-X mental retarda-
tion, and myotonic dystrophy. Hopefully, the nature of each
disease will provide clues regarding the effect of the expan-
sion on the protein product, aided by the loss-of-func-
tion/change-of-function paradigms described above.
Huntington's disease has been a highly visible focus of
efforts to define molecular pathogenesis and the way in
which tri-nucleotide repeat expansions cause disease. It is a
particularly devastating disorder: family members who
inherit the faulty gene in this dominantly inherited disease
show no symptoms until mid- or late-life, whereupon
there is a deterioration of the brain leading to a progressive
loss of motor control and cognitive decline. The cause of
the disorder at the anatomical level is a loss of neurons, par-
ticularly in the corpus striatum and regions of the cerebral
cortex [4,5]. Genetic linkage analysis in large Huntington's
disease pedigrees was used to localize the disease locus to
the tip of chromosome 4 in 1983 [6], with further genetic
and physical mapping leading to the identification of a
novel gene and corresponding protein, 'huntingtin' or
'IT15' [7]. Conserved over a range of species [8] and
expressed in a wide variety of tissues at all developmental
stages [9], huntingtin would appear to have a 'housekeep-
ing' role in all cells. Its expression pattern alone does not
provide any insight into the neuronal specificity of disease
pathogenesis. Lack of homology to other known proteins
or functional protein domains has also left Huntington's
disease researchers at a loss as to the gene's normal function.
The normal huntingtin gene contains a polymorphic
stretch of CAG tri-nucleotide repeats in the beginning of
the protein-coding sequence, predicted to result in
between 8 and 35 glutamines in the normal protein prod-
uct. Huntington's disease is caused by one copy of the
gene containing an abnormally large expansion of this
repeat. Presumably, half of the protein in the huntingtin-
expressing cells of a patient contains 40 or more gluta-
mines instead of the 8-35 glutamines present in the other
half of the cell's protein (from the normal gene). The
inclusion of too many glutamines in the huntingtin pro-
tein is suggestive of a change of function - particularly as
poly-glutamine stretches have been shown to be impor-
tant in the function of DNA-binding proteins involved in
the regulation of transcription [10] - which would
explain the observed dominant inheritance pattern. Until
recently, however, no data had been accumulated con-
cerning the normal function of the huntingtin protein;
such information is critical to understanding the effect of
the tri-nucleotide repeat in the mutant form.
Cross-species conservation of the huntingtin gene has led
to the identification of the murine homologue [8]. To
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study the normal function of the gene, the murine gene
was 'knocked out', using homologous recombination
technology to disrupt the gene at exon 5 [11]. The result-
ing knockout mice were bred to create mutant strains in
which either one or both of the huntingtin alleles are
inactivated. It is important to note that these mice were
not like human patients with Huntington's disease: the
modified genes in the mice are presumed to be loss-of-
function, as a result of the a targeted deletion, whereas the
mutant genes in human patients contain a tri-nucleotide
repeat expansion within the coding sequence (Fig. la).
Interestingly, there is some evidence in the paper [11] that
a 20 kDa protein is produced from the disrupted hunt-
ingtin gene in the brains of heterozygote mice. The
authors assumed, as we will here, that this putative trun-
cated mouse huntingtin is completely inactive, despite the
fact that the truncated protein product would be expected
to contain the poly-glutamine region. The potential of
this truncated protein to disrupt normal neuronal function
should probably not be ignored. With this caveat in mind,
these mice should provide insights into normal gene func-
tion, although their relevance to Huntington's disease
pathophysiology - and in particular to the role of the tri-
nucleotide expansion in changing the protein's function
- is not intuitively clear.
Both the homozygous mutant mice (no good gene copy
- complete loss of function) and the heterozygous mice
(one good gene copy - 50% normal protein) had dis-
tinguishable phenotypes. Homozygotes, but not hetero-
zygotes, showed embryonic lethality at the point of
gastrulation, as assessed by morphologic study of genotyp-
ically determined embryos during development. This is
indicative of a previously undefined role for huntingtin in
early embryogenesis.
Most striking was the observation of cognitive impairment
and focal neuronal deficiency in heterozygous mice
(haplo-insufficient phenotype). The heterozygous mice
were noted to be more sensitive to handling and were fur-
ther assessed for neurological changes at both behavioral
and anatomical levels. Four-month-old, sex-matched het-
erozygote knockout and wild-type control mice were sub-
jected to a battery of tasks designed to measure several
aspects of cognition, including: motor activity testing
(spontaneous motor activity in a horizontal plane); T-
maze alternation testing (short-term memory and dis-
criminative learning); radial-arm maze testing (working
memory); and the Morris water maze task (spatial infor-
mation acquisition). Knockouts performed differently
from the controls on two of the tests, showing increased
spontaneous motor activity as well as difficulty unlearning
previously learned behavior in the Morris water maze
task. Morphometric histological comparison of heterozy-
gous knockout and wild-type brain structures revealed a
significant decrease in the total number of neurons in the
subthalamic nucleus, as well as a suggestive decrease in the
globus pallidus, in the knockouts. Histological hallmarks
of human Huntington's disease, such as marked decrease
in striatal neurons and reactive gliosis, were not features of
the knockout brains. The combination of cognitive
impairment and regionally specific neuronal deficits in
heterozygous knockout mice argues strongly for cross-
species conservation of a critical role for huntingtin in
brain function.
What insights have these knockout mice provided into the
human disorder and the issue of tri-nucleotide repeat
disorders? Unfortunately, it seems that the mice have, so
far, served only to deepen the enigmatic nature of Hunt-
ington's disease. Four observations seem relevant. First, the
heterozygous mice have a phenotype that is not terribly
dissimilar to humans heterozygous for the expansion
mutation that causes Huntington's disease; this is not what
one would expect when comparing a dominantly inher-
ited (change-of-function?) disease like Huntington's to
a knockout (loss of function), unless having 50 % of
huntingtin is not enough for normal brain function
Fig. 1. Human Huntington's disease
patients and the mouse knockout
heterozygotes differ at the DNA, mRNA
and protein levels. The mutant human
huntingtin gene contains a CAG repeat
expansion that results in the production
of an expanded mRNA, as well as a
protein containing an expanded poly-
glutamine tract. The effect of the
expansion on protein function,
speculated to be a change of function,
remains unknown. The mouse mutant
huntingtin gene is disrupted at exon 5,
resulting in the production of mRNA and
a truncated protein assumed to have lost
all function. Normal DNA alleles and
mRNA products are not shown.
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(haplo-insufficiency). Second, homozygous knockout
mice die as embryos, whereas human Huntington's disease
homozygotes are externally similar to heterozygotes, and
there is no evidence for increased fetal demise [11,12]; this
suggests that the excessive number of glutamines has little
bearing on function in the human embryo, yet has a pro-
found effect on huntingtin function in the adult nervous
system. Third, young huntingtin-deficient homozygous or
heterozygous mice seem to be phenotypically abnormal,
whereas humans are rarely affected before mid-life, and
then are faced with a progressive decline in abilities; this
suggests a cumulative toxic effect of mutant huntingtin in
humans, again consistent with a change of function as a
result of the expansion mutation. Fourth, in heterozygous
mice, the focus of the neuronal deficit is in the subthala-
mic nucleus and globus pallidus, with sparing of the cau-
date and putamen, whereas in heterozygous humans, the
subthalamic nucleus can be relatively spared, while the
caudate and putamen are heavily involved [13]; this could
be due to species differences, but may also reflect the
effects of a change of function in human mutant hunt-
ingtin (rather than loss of function, as in the mouse) that
results in more widespread neuronal damage.
It seems that in the post-huntingtin-gene knockout era,
three pathogenic mechanisms must be considered for the
abnormal tri-nucleotide repeat in the huntingtin gene.
First, and most probable, is a change of function of the
huntingtin protein in Huntington's disease patients. Under
this model, the change, due to an increased number of
glutamines, has no bearing on fetal development. Second,
a dominant-negative effect remains a possibility: the
mutant huntingtin may form oligomers with the normal
protein and destroy the function of an as-yet unidentified
complex. Again, this requires that the dominant-negative
effect does not occur during embryonic life. Finally,
haplo-insufficiency through tri-nucleotide repeat-induced
inactivation of a huntingtin domain critical for neural, but
not embryonic, protein function should be considered.
This would explain the phenotype observed in heterozy-
gous mice (in homozygotes, the neural effects would
never be seen, due to early lethality), as well as the appar-
ent absence of any fetal effect in human homozygotes.
Weighing in against this is the observation that an individ-
ual human exists who has only a single functioning hunt-
ingtin gene (loss-of-function of the other allele resulting
from a chromosomal abnormality) and who is normal at
nearly 50 years of age [14].
Clearly, sorting out these possibilities will require an
understanding of the biochemistry and cell biology of
huntingtin, and of the effect of the tri-nucleotide repeat
on the gene, RNA and protein function. In this context,
it is important to note that tri-nucleotide expansions in
other diseases seem to exert their pathogenic effects by
novel mechanisms. In fragile X, a common form of inher-
ited mental retardation, the expanded CGG sequence
causes hypermethylation of the gene's promoter, loss of
transcription, and the expected loss-of-function in this
X-linked recessive disorder [15]. In myotonic dystrophy, a
highly clinically variable yet common muscular dystrophy,
the expansion seems to disrupt RNA metabolism through
precipitation of RNA molecules containing the expansion
[16,17]. This dominantly inherited disorder has been pro-
posed as the first 'dominant-negative RNA disorder' [17],
although this needs to be investigated more thoroughly.
Perhaps the next step towards elucidating the effect of the
Huntington's disease triplet expansion will be the devel-
opment of mice transgenic for the expanded gene in the
contexts of normal and absent wild-type gene function.
Maybe then the enigma of Huntington's disease will
shrink to the point where a rational therapeutic strategy
can be evolved.
References
1. Hoffman EP, Lehmann-Horn F, Rudel R: Overexcited or inactive: ion
channels in muscle disease. Cell 1995, 80:681-686.
2. Byers PH: Disorders of collagen biosynthesis and structure. In The
Metabolic Basis of Inherited Disease, 7th edition. Edited by Scriver CR,
Beaudet AL, Sly WS, Valle D. New York: McGraw-Hill; 1995:
4029-4077.
3. Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol
homeostasis. Science 1986, 232:34-37.
4. Folstein SE: Huntington's Disease: A Disorder of Families. Baltimore:
The Johns Hopkins University Press; 1989.
5. Hoffman EP, Jaffurs D: An expanding enigma. Curr Biol 1993,
3:456-459.
6. Guesella F, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi
RE, Watkins PC, Ottina K, Wallace MR, Sakaguchi MR, et al.: A poly-
morphic DNA marker genetically linked to Huntington's disease.
Nature 1983, 306:234-238.
7. Huntington's Disease Collaborative Research Group: A novel gene con-
taining a trinucleotide repeat that is expanded and unstable on Hunt-
ington's disease chromosomes. Cell 1993, 72:971-983.
8. Lin B, Nasir J, MacDonald H, Hutchinson GB, Graham RK, Rommens
JM, Hayden MR: Sequence of the murine Huntington disease gene: evi-
dence for conservation, alternate splicing and polymorphism in a
triplet (CCG) repeat. Hum Mol Genet 1994, 3:85-92.
9. Strong TV, Tagel DA, Vades M, Elmer LW, Boehm K, Swaroop M,
Kaatz KW, Collings FS, Albin RL: Widespread expression of the human
and rat Huntington's disease gene in brain and nonneural tissues.
Nature Genet 1993, 5:259-265.
10. Gerber HP, Seipel K, Geargiev 0, Hofferer M, Hug M, Rusconi S,
Schaffner W: Transcriptional activation modulated by homopolymeric
glutamine and proline stretches. Science 1994, 263:808-810.
11. Nasir J, Floresco SB, O'Kusky JR, Diewert VM, Richman JM, Zeisler ,
Borowski A, Marth JD, Phillips AG, Hayden MR: Targeted disruption of
the Huntington's disease gene results in embryonic lethality and
behavioral and morphological changes in heterozygotes. Cell 1995,
81:811-823.
12. Fahn S: Huntington disease. In Merritt's Textbook of Neurology, 9th
edn. Edited by Roland LP. Baltimore: Williams and Wilkins;
1995:695-699.
13. Oppenheimer DR, Esiri MM: Diseases of the basal ganglia, cerebellum
and motor neurons. In Greenfield's Neuropathology, 5th edn. Edited by
Adams JH, Duchen LW. London: Edward Arnold; 1992:988-1045.
14. Ambrose CM, Duyao MP, Barnes G, Bates GP, Lin CS, Srinidhi J, Bax-
endale S, Hummerich H, Lehrach H, Altherr M et al.: Structure and
expression of the Huntington's disease gene: evidence against simple
inactivation due to an expanded CAG repeat. Somat Cell Mol Genet
1994, 20:27-38.
15. Pieretti M, Zhang F, Fu YH, Warren ST, Oostra BA, Caskey CF, Nelsen
DL: Absence of expression of the FMR-1 gene in Fragile-X syndrome.
Cell 1991,66:817-822.
16. Taneja KL, McCurrach M, Schalling M, Housman D, Singer RH: Foci of
trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells
and tissues. Cell Biol 1995, 128:995-1002.
17. Wang J, Pegoraro E, Menegazzo E, Gennarelli M, Hoop RC, Angelini C,
Hoffman EP: Myotonic dystrophy: evidence for a possible dominant-
negative RNA mutation. Hum Mol Genet 1995, 4:599-606.
W Gregory Feero and Eric P. Hoffman, Departments of
Molecular Genetics and Biochemistry, Human Genetics,
and Pediatrics, University of Pittsburgh School of
Medicine, Pittsburgh, Pennsylvania 15261, USA.
